Spinal Cord Clinical Trials 2024

Spinal Cord Clinical Trials 2024

Spinal Cord research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in spinal cord clinical trials today.

Spinal Cord Clinical Trials

Here are the 6 most popular medical studies for spinal cord

Popular filter options for spinal cord trials

Spinal Cord Injury Clinical Trials

View 71 Spinal Cord Injury medical studies.

Chicago, Illinois

Gait Training with Lexapro for Spinal Cord Injury

Recruiting1 awardPhase 1
Chicago, Illinois

The primary goal of the proposed clinical trial is to investigate the combined effects of walking training and monoaminergic agents (SSRIs and TIZ) on motor function of individuals in sub-acute (2-7 mo) human motor incomplete Spinal Cord Injury (SCI), with a primary emphasis on improvement in locomotor capability. We hypothesize that the use of these drugs applied early following SCI may facilitate independent stepping ability, and its combination with intensive stepping training will result in improved locomotor recovery following incomplete SCI. Loss of descending control via norepinephrine inputs following spinal cord injury can impair normal sensorimotor function through depressing motor excitability and impairing walking capacity. Replacing these inputs with drugs can alter the excitability and assist with reorganization of locomotor circuits. Assessment of single-dose administration of these agents has been tested in patients with motor incomplete spinal cord injury; only limited changes in walking performance have been noted. The resultant onset of weakness and increase in involuntary reflexes following motor incomplete SCI may partly be a result of damage to descending pathways to the spinal cord that control the release of serotonin. In models of SCI, for example, application of agents that simulate serotonin has been shown to change voluntary motor behaviors, including improvement of walking recovery. In humans following neurological injury, the effects of 5HT agents are unclear. Few previous reports indicate improved motor function following administration of agents which enhance the available serotonin in the brain, although some data suggests that increased serotonin may be beneficial. In this application, we propose to study the effects of clinically used agents that increase or decrease intrinsic serotonin activity in the brain on strength and walking ability following human motor incomplete SCI. Using detailed electrophysiological recordings, and biomechanical and behavioral measures, we will determine the effects of single or chronic doses of these drugs on voluntary and involuntary motor behaviors during clinical measures and walking measures. The novelty of this proposed research is the expectation that agents that increase serotonin activity may increase abnormal reflexes in SCI, but simultaneously help to facilitate motor and walking recovery. Despite potential improvements in voluntary function, the use of pharmacological agents that may enhance spastic motor behaviors following SCI is in marked contrast to the way in which drugs are typically used in the clinical setting.

CSCI Clinical Trials

View 71 CSCI medical studies.

Chicago, Illinois

Gait Training with Lexapro for Spinal Cord Injury

Recruiting1 awardPhase 1
Chicago, Illinois

The primary goal of the proposed clinical trial is to investigate the combined effects of walking training and monoaminergic agents (SSRIs and TIZ) on motor function of individuals in sub-acute (2-7 mo) human motor incomplete Spinal Cord Injury (SCI), with a primary emphasis on improvement in locomotor capability. We hypothesize that the use of these drugs applied early following SCI may facilitate independent stepping ability, and its combination with intensive stepping training will result in improved locomotor recovery following incomplete SCI. Loss of descending control via norepinephrine inputs following spinal cord injury can impair normal sensorimotor function through depressing motor excitability and impairing walking capacity. Replacing these inputs with drugs can alter the excitability and assist with reorganization of locomotor circuits. Assessment of single-dose administration of these agents has been tested in patients with motor incomplete spinal cord injury; only limited changes in walking performance have been noted. The resultant onset of weakness and increase in involuntary reflexes following motor incomplete SCI may partly be a result of damage to descending pathways to the spinal cord that control the release of serotonin. In models of SCI, for example, application of agents that simulate serotonin has been shown to change voluntary motor behaviors, including improvement of walking recovery. In humans following neurological injury, the effects of 5HT agents are unclear. Few previous reports indicate improved motor function following administration of agents which enhance the available serotonin in the brain, although some data suggests that increased serotonin may be beneficial. In this application, we propose to study the effects of clinically used agents that increase or decrease intrinsic serotonin activity in the brain on strength and walking ability following human motor incomplete SCI. Using detailed electrophysiological recordings, and biomechanical and behavioral measures, we will determine the effects of single or chronic doses of these drugs on voluntary and involuntary motor behaviors during clinical measures and walking measures. The novelty of this proposed research is the expectation that agents that increase serotonin activity may increase abnormal reflexes in SCI, but simultaneously help to facilitate motor and walking recovery. Despite potential improvements in voluntary function, the use of pharmacological agents that may enhance spastic motor behaviors following SCI is in marked contrast to the way in which drugs are typically used in the clinical setting.

Spinal Cord Clinical Trials With No Placebo

View 94 spinal cord medical studies that do not have a placebo group.

View More Spinal Cord Trials

See another 75 medical studies focused on spinal cord.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to spinal cord

What are the top hospitals conducting spinal cord research?

When it comes to pushing the boundaries of medical research in spinal cord treatments, several hospitals are leading the way. In Chicago, the Shirley Ryan AbilityLab is at the forefront with six ongoing clinical trials focused on spinal cord injuries. Known for its world-class rehabilitation services, this institution is driven by a commitment to helping patients regain their mobility and independence after such life-altering incidents.

Meanwhile, in West Orange, New jersey, the Kessler Foundation is making significant strides with five active spinal cord trials. As a renowned research center dedicated to improving quality of life for individuals with disabilities, their focus on understanding and treating spinal cord injuries showcases their dedication to advancing scientific knowledge.

Further south in sunny Miami, researchers at the University of Miami are working diligently on four active clinical trials targeting spinal cord conditions. Located near beautiful beaches and vibrant culture-rich neighborhoods that embody resilience and determination–qualities mirrored within each participant striving toward recovery from these challenging injuries

Not too far away in Ann Arbor lies another formidable player in this field: The University of Michigan. With four ongoing clinical trials devoted exclusively to studying spinal cord injuries under their belt; they demonstrate unwavering commitment towards enhancing treatment strategies aimed at restoring function and improving outcomes.

Lastly, Thomas Jefferson University located in Philadelphia joins these esteemed institutionswith its own setof four currentspinalcordclinicaltrials underway.As oneofthe oldestandmost prestigiousacademicmedicalcentersintheUnitedStates,it embodiesa richhistoryof innovationandadvancementin healthcare.Throughtheirresearcheffortsfocusedonspinalcordinjuries,TJUiscontributingtothepoolofknowledge,andhopesarehighthattheirfindingswilltranslateintobreakthroughtreatmentsforpatientsaroundtheworld.Diverseyetunitedinthecommonpurposeofbringinghopeandleadingchange,institutionslikethesefosteracultureoffearlesscuriosityandtenacitytocombatoneofthemostchallengingconditionsthatcandevastatepeople'slives.

Which are the best cities for spinal cord clinical trials?

When it comes to spinal cord clinical trials, several cities have emerged as frontrunners in research and development. Chicago, Illinois leads the pack with 12 active trials focused on advancements such as Acute Intermitted Hypoxia, Neurostimulation for respiratory function after spinal cord injury, and Enhanced Medical Rehabilitation (EMR). Houston, Texas is also a key player with 12 ongoing studies exploring treatments like MT-3921 and mindfulness meditation (MM). Miami, Florida follows closely behind with 9 active trials investigating Mindfulness Exercise Group and Paralyzed Veterans of America (PVA) Cardio-Metabolic Disease (CMD) Consumer Guide Group among others. Lastly, Philadelphia, Pennsylvania boasts 9 active trials examining innovations like Neuro-Spinal Scaffold and Augmented Blood Pressure. These cities offer individuals dealing with spinal cord injuries access to cutting-edge clinical trials that hold promise for improved care outcomes.

Which are the top treatments for spinal cord being explored in clinical trials?

Exciting advancements in spinal cord treatments are unfolding through dedicated clinical trials. One standout treatment being explored is stem cell therapy, which holds great promise for regenerating damaged nerve cells. Another innovative approach involves the use of electrical stimulation to activate and retrain the spinal cord, aiding in functional recovery. Additionally, gene therapies that target specific genetic mutations associated with spinal cord injuries are showing encouraging results. As researchers continue their relentless pursuit of breakthroughs, these top treatments offer hope for improved outcomes and quality of life for those affected by spinal cord conditions.

What are the most recent clinical trials for spinal cord?

Exciting advancements are being made in the realm of spinal cord research, with recent clinical trials offering potential breakthroughs for patients. One such trial is investigating NVG-291, an injection specifically developed for spinal cord treatment. Additionally, researchers are exploring the effectiveness of Clemastine Fumarate as a possible therapy option. Another groundbreaking study focuses on Gadoquatrane - an approved macrocyclic GBCA that shows promise in improving outcomes for those with spinal cord injuries. Furthermore, remote CMR and exercise interventions are being tested to enhance the management and rehabilitation of individuals with paraplegia caused by spinal cord conditions. These latest trials hold great promise in advancing our understanding and care for people affected by spinal cord issues.

What spinal cord clinical trials were recently completed?

Recently completed clinical trials focused on spinal cord treatments have made significant strides in advancing our understanding and potential therapies for this debilitating condition. Notably, the trial sponsored by Acorda Therapeutics investigated their promising therapy CVT-301 and concluded in February 2021. Similarly, a study led by Novartis Pharmaceuticals examined the efficacy of BAF312 and reached completion in November 2020. These milestones mark important achievements in the pursuit of improved treatments for spinal cord-related disorders, offering hope to patients seeking better outcomes and quality of life.